表紙
市場調查報告書

市場焦點:諾羅病毒

Market Spotlight: Norovirus

出版商 Datamonitor Healthcare 商品編碼 939989
出版日期 內容資訊 英文 21 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:諾羅病毒 Market Spotlight: Norovirus
出版日期: 2020年04月23日內容資訊: 英文 21 Pages
簡介

本報告提供全球諾羅病毒治療藥市場相關調查分析,提供主要的上市藥·開發平台藥物,臨床試驗,最近的趨勢,未來趨勢,成功概率,專利資訊,10年預測等相關的系統性資訊。

目錄

概要

要點

疾病的背景

治療

流行病學

  • 諾羅病毒的爆發
  • 疫苗開發的課題

開發平台藥物

成功概率

臨床試驗形勢

  • 贊助商:各狀態
  • 贊助商:不同階段

參考文獻

附錄

目錄
Product Code: DMKC0183940

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, key upcoming events, and an epidemiological overview.

Key Takeaways:

  • Worldwide, about one out of every five cases of acute gastroenteritis is caused by norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
  • Globally, norovirus is estimated to cause approximately 200,000 deaths annually, including an estimated 70,000 child deaths, mainly in developing countries.
  • The largest proportion of industry-sponsored drugs in active clinical development for norovirus are in Phase I. All clinical candidates currently in the pipeline for norovirus are vaccines. These drugs are administered via the oral, intranasal, and intramuscular routes.
  • The overall likelihood of approval of a Phase I antiviral asset is 14.3%, and the average probability a drug advances from Phase III is 74.4%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
  • The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.
  • The US has a substantial lead in the number of norovirus clinical trials globally. Clinical trial activity in the norovirus space is dominated by completed trials. Takeda has the highest number of completed clinical trials for norovirus, with 12 trials.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for norovirus.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

  • Norovirus outbreaks
  • Challenges for vaccine development

PIPELINE DRUGS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for norovirus in the US
  • Figure 2: Pipeline drugs for norovirus, by company
  • Figure 3: Pipeline drugs for norovirus, by drug type
  • Figure 4: Pipeline drugs for norovirus, by classification
  • Figure 5: Probability of success in the norovirus pipeline
  • Figure 6: Clinical trials in norovirus
  • Figure 7: Top 10 drugs for clinical trials in norovirus
  • Figure 8: Top 10 companies for clinical trials in norovirus
  • Figure 9: Trial locations in norovirus
  • Figure 10: Norovirus trials status
  • Figure 11: Norovirus trials sponsors, by phase

LIST OF TABLES

  • Table 1: Pipeline drugs for norovirus in the US"